OKYO Pharma Announces Director Acquires Shares

Summary by AI BETAClose X

OKYO Pharma Limited announced that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on NASDAQ at $1.61 per share, increasing his total holding to 31,201 shares. This follows recent positive Phase 2a data for Urcosimod in neuropathic corneal pain and the company's plans to initiate a ~150 subject Phase 2b/3 study in the first half of the year.

Disclaimer*

UK 100

Latest directors dealings